blog-icon

Clinical research blog

Explore our blog for insights into the big questions in precision medicine and clinical research.

The psychology of kit return: What drives completion?

Genetic testing has become a core component of patient identification and stratification in modern clinical trials, particularly in rare disease and precision m...
Continue reading

Podcast recap: Andrea Ganna on applying polygenic scores and EHRs in healthcare

On the latest episode of The Genetics Podcast, Patrick welcomed Dr. Andrea Ganna, an Associate Professor at the Institute for Molecular Medicine Finland (FIMM),...
Continue reading

Connecting patients to rare disease trials through scalable genetic testing infrastructure

At Seqera Sessions London 2026, Dr. Katie Barnes, Head of Clinical Genetics at Sano Genetics, outlined a practical challenge facing the field: how to move from ...
Continue reading

How strong eligibility signals unlocked scale in Parkinson’s trials

Recruitment in genetically stratified clinical trials is often constrained by a simple problem: large screening volumes do not translate into eligible patients....
Continue reading

Precision liver study completes 1-year recruitment of nearly 1,000 participants using existing NHS data

Somerset, UK, 18th March 2026: Predictive Health Intelligence (PHI) and Sano Genetics today announced the completion of recruitment into the LiveWell study, wit...
Continue reading

Podcast recap: Anna Lindstrand on implementing short-read and long-read sequencing for rare disease diagnostics

Genome sequencing is now a core part of rare disease diagnostics in several healthcare systems. However, the path from sequencing technology to clinical impact ...
Continue reading

Patient engagement and education insights from rare disease trials

Recruiting and retaining patients in rare disease and genomic medicine research requires more than outreach. Many participants need support understanding geneti...
Continue reading

Podcast recap: Matthew Goldstein on expanding access to genetic screening

Genetic screening has advanced rapidly over the past two decades. Sequencing is faster and far less expensive, and the ability to interpret genetic variants con...
Continue reading

Why site selection is failing rare disease trials and what to do differently

Rare disease trials operate under structural constraints that make site selection more important than in common disease programs. Patient populations are small,...
Continue reading

Rare disease drug development requires designing for access from day one

Rare disease innovation has accelerated in recent years, particularly in cell and gene therapy (CGT). Yet for drug developers, one challenge remains persistent:...
Continue reading